JimJimJimJim Posted September 11, 2014 Share Posted September 11, 2014 Jim Marshall (not a doctor) said ... A few hours ago the drug Xtandi (enzalutamide) was approved for use before chemotherapy in the USA for men who have metastatic castration-resistant prostate cancer. This means that men in the USA with cancer that has spread that isn't controlled by their ordinary hormone therapy may choose to have either Xtandi (enzalutamide) or Zytiga (abiraterone) before they have to use chemotherapy with Taxotere (docetaxel). In Australia the PBS will pay for Xtandi or Zytiga only after chemotherapy with Taxotere at the moment. A panel of experts (the PBAC) recently turned down Zytiga before chemotherapy as being too expensive for the PBS, partly because of the price the company was offering. Because of this USA FDA approval, we can expect the Medivation company will apply to have their drug Xtandi approved to go on the PBS sometime in the near future. Of course, approval, as always, will depend on "bangs per buck". ... end Jim Click this sentence to see the press release. OR http://tinyurl.com/m33unl4 Link to comment Share on other sites More sharing options...
This topic is now archived and is closed to further replies.